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“Characterization of mitochondrial dysfunction in neural cell model of 
Parkinson’s disease”
 
The main focus of the project is the characterization of mitochondrial dysfunction in neural cell  
models of Parkinson’s disease (PD). 
The first  purpose was to investigate how Rotenone,  a  known neurotoxin,  and H2O2,  a known 
cytotoxic oxidant, reproduce a PD-related cell damage. Using MTT and Neutral Red viability assays,  
was then observed how these substances modulate cell death.
Secondary how mitochondrial impairment influences mitochondrial associated proteins, DJ-1 and 
Nrf2,  linked  to  the  pathophysiology  of  PD.  Loss  of  DJ-1  is  recruited  by  mitochondria  under 
conditions of oxidative stress and can influence the translocation of Nrf2 to the nucleus to activate 
the antioxidant response element. Defects in DJ-1 have been identified in some familial forms of 
Parkinson’s disease and impairment of the antioxidant response is strongly linked to idiopathic 
cases. The effect of specific PD-related neurotoxins mitochondrial associated proteins was studied 
using SDS-PAGE gel electrophoresis and Western blotting. 
At  last  the  project  was  extended  to  investigate  the  molecular  events  that  occur  during 
mitochondrial dysfunction and whether this phenomenon can be modulated to maintain neuronal 
cell survival. In particular it has been analysed how the growth factors produced by Glioma cells 
culture  could  module  the  neuronal  viability,  in  normal  growth  conditions  and  in  neurotoxic 
conditions. The role that these factors may play in maintaining glial cell function is also of interest 




Parkinson’s disease (PD) is  the second most common neurodegenerative disorder of the aging 
brain after Alzheimer’s disease. It is a progressive neurological movement disorder characterized 
by  the  selective  degeneration  of  dopaminergic  neurons,  mainly  in  the  Substantia  Nigra  pars 
compacta, and the presence of proteinaceous intraneural inclusions known as Lewy bodies (Dauer 
et al., 2003).
The death of nigral dopaminergic neuron leads to a loss of the neurotransmitter dopamine in the 
striatum and consequent dysregulation of basal ganglia circuitries accounting for motor symptoms 
of PD such as resting tremor, slowness of voluntary movements, progressive rigidity and postural 
instability (Hardy at al.,2006). 
Lewy bodies are spherical eosinophilic cytoplasmic aggregates composed of a variety of proteins 
including  α-synuclein,  ubiquitin,  molecular  chaperones  and neurofilaments  (Lees  at  al.,  2009).  
These deposits are associated with non-motor features of PD such as autonomic dysfunctions, 
sleep disturbances, depression and cognitive impairments (Braak et at., 2005). 
Current  treatments, involving maintenance of dopamine levels, alleviate the motor dysfunction 
symptoms but do not prevent neurodegeneration due to the fact that researches are still unclear 
on the exact pathways directly causing neuronal cell death (Dawson et al., 2010). 
The lack of a treatment for PD is the main motivation to study possible molecular mechanisms and  
to  discover  the exact  pathophysiology of  the disease.  Several  hypothesis  have been proposed 
including  mitochondrial  dysfunctions,  protein  degradation  impairment,  neuroinflammation, 
oxidative stress, calcium homeostasis defects, lysosomal alterations and excitotoxicity (Navarro and 
Boveris,  2009).  Although  these  features  are  linked,  abnormal  protein  aggregation  and 
mitochondrial  dysfunctions  due  to  the  increase  in  oxidative  stress  are  believed  to  primarily 
compromise neuronal survival (Nicholls and Budd, 2000). 
1.2 Function and dysfunction of Mitochondria
Mitochondria are membrane-enclosed organelles which contain genetic material independent of 
nuclear DNA. These organelles produce most of the cell energy in the form of ATP along with their 
roles in signalling, cellular differentiation, cell growth and cell death.
The structure of a mitochondrion includes outer and inner membranes, intermembrane space and 
internal matrix. The inner membrane consists of the electron transport system complex, the ATP 
synthetase complex and transport  proteins so as  to be the site  of  energy production through 
oxidative phosphorylation. Depending on this process there are five intermembrane complexes 
(Complex I, II, III, IV, V) and two mobile electron carriers (Coenzyme Q and Cytocrome c).  
As  these  organelles  are  one  of  the  main  sources  of  reactive  oxygen  species  (ROS),  they  can 
themselves be affected by oxidative damage which can also turn into an apoptotic mechanism, the 
process  of  programmed  cell  death  (Hwang,  2013).  Many  apoptotic  responses  occur  in 
mitochondria such as the altered electron transport,  the loss of membrane potential, the release 
of Caspase regulators, the attendance of pro- and anti- apoptotic family proteins. Therefore, it is 
plausible  that  the effect  of  mitochondrial  dysfunctions  can play a  role in aging processes  and 
degenerative diseases as PD (Lin et al., 2009).
1.3 Mitochondrial dynamics in PD
The direct relationship between mitochondrial dysfunction and PD comes from the post-mortem 
description  of  the  Complex  I  deficit  in  the  Substantia  Nigra  of  patients  with  PD.  In  a  study  
performed by Schapira et al. in 1990, the structure and the function of mitochondrial respiratory-
chain  enzyme  proteins  were  analysed  post-mortem  in  the  substantia  nigra  of  patients  with 
Parkinson's disease. Total protein and mitochondrial mass of the PD patients were similar to the 
controls,  whereas NADH-ubiquinone reductase (Complex I)  and NADH cytochrome c reductase 
activities were significantly reduced. 
Following studies identified a similar Complex I reduction in blood platelets, lymphocytes, muscle  
tissue and frontal cortex from PD patients. (Krige et al., 1992. Barroso et al., 1993. Penn et al.,  
1995.)  However,  it  appears  that  the  Substantia  Nigra  is  more  vulnerable  to  impairments  of 
Complex I activity than the other regions and peripheral organs. In fact the increased levels of ROS  
generated  within  Dopamine  neurons,  as  a  result  of  Dopamine  metabolism,  lead  to  increased 
intracellular oxidative stress and reduced ATP production (Chinta and Andersen, 2008).
Complex I (NADH-quinone oxidoreductase) is one of the "entry enzymes" of cellular respiration. It 
is located in the inner mitochondrial membrane and it catalyses the transfer of electrons from 
NADH to Coenzyme Q10 (Ubiquinone). During both forward and reverse electron transfer, Complex 
I is a potential source of toxic ROS like superoxide and hydrogen peroxide. In particular, Superoxide 
contributes  the  most  to  cellular  oxidative  stress  and  cell  death  and  it  is  thus  linked  to 
neuromuscular diseases and aging. 
As  oxidative  stress  and  alterations  in  levels  of  antioxidants  have  been  linked  to  the 
neurodegeneration, this has lent more evidence to the role of mitochondrial dysfunctions in PD 
(Dauer et al., 2003). Consistent with the systemic low-grade Complex I activity associated with PD, 
the second observation of Schapira et al. in 1990 was that this biochemical Complex I defection 
was  the  same  as  the  one  produced  in  animal  models  of  parkinsonism by  1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP).  Further  support  to the proposition  that  Parkinson's  disease 
could be due to an environmental toxin with action similar to MPTP was given by Betarbet et al. in 
2000, studying the effect of rats exposure to Rotenone. 
Rotenone is a natural compound extracted from tropical plants and used as a pesticide that binds 
to the Ubiquinone binding site of Complex I and leaks electrons causing oxidative damage and cell  
toxicity  (Kurshnareva  et  al.  2002).  Afterwards  chronic  Rotenone  treatments  to  rats  result  in 
neuropathological and behavioural changes similar to human PD, including selective nigrostriatal 
degeneration and α-synuclein deposits (Sherer et al., 2003). Therefore chronic Complex I inhibition 
lead to destruction  of  substantia  nigra par  compacta  neuron processes,  morphologic  changes, 
neural loss and decreased  tyrosine hydroxylase protein levels in rodent postnatal midbrains (Testa 
et al., 2005).
1.4 PD-related genes and proteins 
Most cases of PD are sporadic but there is a number of rare instances where PD is familial. Recent 
studies  indicate  that  several  PD-related  genes,  directly  or  indirectly,  influence  mitochondrial  
integrity providing a specific link to the mitochondrial dysfunctions observed in sporadic PD cases. 
(Hardy et al., 2006) The protein products of PD-associated genes include the E3 ubiquitin ligase 
Parkin, the PTEN-induced kinase 1 (PINK1), the redox-regulated chaperone DJ-1, the Leucine-rich 
Repeat  Kinase  2  (LRRK2),  the  ubiquitin  C-terminal  hydrolase  L1  (UCH-L1)  and the  presynaptic  
protein α-synuclein (SNCA). 
Figure  : PD-related proteins  pattern (Blesa et al., 2015)
The characterization of these genes again demonstrates the causal involvement of mitochondrial  
impairment  and  oxidative  stress  in  PD  pathogenesis,  as  several  of  them  carry  out  important 
functions  within  mitochondria  and act  to  reduce  intracellular  oxidative  stress  (Bonifatti  et  al., 
2003). 
Functional studies in cellular and animal models have shown that Parkin, PINK1 and DJ-1 mutations 
are primary cause of early autosomal recessive forms of PD (Fitzgerald and Plun-Favreau, 2008).  
They  are  part  of  a  pathway that  is  involved  in  maintaining  the  mitochondrial  integrity  within 
certain tissue, including dopaminergic neurons in the brain. They seem to work together to help 
maintain  mitochondrial  homeostasis  but  their  mechanism  and  their  relationship  still  remain 
unclear.
1.5 PINK1
PTEN-induced kinase 1 is a serine/threonine kinase mainly localized in mitochondrial environment 
and present in the cytoplasm under the influence of particular cell conditions. The action of this 
kinase is required for mitochondrial protection as it prevents oxidative stress-induced release of  
cytochrome c and consequent apoptosis (Bueler, 2009). 
In fact PINK1 phosphorylates two proteins localized in the mitochondrial intermembrane space, 
TRAP1 (TNF-receptor-associated protein 1) and HtrA2/Omi. Phospho-TRAP1 inhibits cytochrome c 
release and then acts as a chaperon to prevent misfolding or promote assembly of mitochondrial 
proteins under oxidative stress conditions (Pridgeon et al., 20017. Plun-Favreau et al., 2007).
1.6 Parkin
Parkin  is  a  cytosolic  E3 ubiquitin-protein  ligase  that  promotes  the degradation  of  unfolded or 
impaired  proteins  by  the  proteasome  system.  An  increase  of  oxidative  stress,  that  induces 
mitochondrial malfunction, triggers a rapid and specific translocation of the cytosolic Parkin to the 
mitochondria which manifest a reduced membrane potential (Shimura et al., 2000). 
Within  the  mitochondrion,  Parkin  promotes  Mytophagy,  the  lysosome degradation  process  of 
damaged mitochondria (Bueler, 2009). Furthermore Parkin acts as a potent cell protector factor 
inhibiting the cytochrome c release and suppressing pro-apoptotic effectors that lead to caspase 
activation and cell death by apoptosis (Darios et al., 2003. Kuroda et al.,2006).
Parkin effects are facilitated by the cytosolic PINK1 phosphorylation that triggers its translocation 
from the cytosol into the mitochondrion. However this phosphorylation is not essential as Parkin 
activity has been found unchanged in PINK1-deficient cells (Kim et al., 2008). 
1.7 DJ-1 
DJ-1 was first linked to PD when deletion mutations in its gene were discovered to cause a familial  
early  form  of  the  disease  (Bonifati  et  al.,  2003).  In  fact  DJ-1  is  an  oxidative  stress-regulated 
chaperone and transcriptional modulator that shifts from the cytosol to mitochondria and to the 
nucleus upon oxidation of specific cysteine residues (Canet-Aviles et al.,2004). 
Under basal condition it is present mostly in the cytosol, but under oxidative stress conditions it 
redistributes to mitochondria  and later  to the nucleus correlating the ability  of  DJ-1 to confer 
neuroprotection (Junn et al.,2009). DJ-1 mitochondrial translocation starts with the oxidation of 
the cysteine residue 106, to the cysteine-sulfinate and then cysteine-sulfonate, which is probably 
facilitated  by  binding  to  other  mitochondrial  chaperons  (Li  et  al.,2005).  Because  of  these 
characteristics, DJ-1 thus possesses quenching activity against ROS by self-oxidation of its cysteine 
residues (Taira et al.,2004).
Figure  : DJ-1 functions and its related diseases (Ariga et al, 2013). 
As  a  chaperon  DJ-1  prevents  the  misfolding  and  the  aggregation  of  oxidized  mitochondrial  
proteins, like alpha-synuclein, suggesting a protective role against electron transport chain activity 
impairments. Moreover, loss of function or mutations of DJ-1 render animals and cultured cells 
more susceptible to oxidative stress and mitochondrial toxins, as Complex I inhibitors, implicated in 
sporadic PD. This suggests that other possible target of DJ-1 would be subunits of mitochondrial  
respiratory  complexes and in particular of Complex I (Lev et al., 2007).
As a transcriptional modulator DJ-1 regulates the activity of DNA-binding transcription factors such 
as p53, Nuclear factor erythroid-2-related factor 2 (Nrf2), sterol regulatory element binding protein 
(SREBP),  androgen receptor  and  polypyrimidine  tract-binding  protein-associated  splicing  factor 
(PSF). 
 1.8 Nrf2
Nrf2 is a transcription factor located within the cytosol of the cell  and regulated by a cytosolic  
protein  called  Kelch-like  ECH-associated  protein  1  (Keap1).  Keap1  binds  Nrf2  and  regulates  it 
negatively  by  promoting  its  sequestration  in  the  cytosol  and  its  degradation.  Unless  Nrf2  is 
activated,  it  is  ubiquitinated by the E3-ubiquitin ligase-like  domain of  Keap1 and degraded by 
proteasome. Signals of oxidative stress,  as the presence of DJ-1 within the cytosol,  induce the 
separation  of  Nfr2  from  Keap1  and  suddenly  its  translocation  into  the  nucleus.  Following  its 
nuclear translocation, Nrf2 binds the antioxidant response elements (ARE) in the promoter region 
of  its  target  genes  (Tufekci  et  al.,  2011)  activating  the  antioxidant  defence  system  and 
mitochondrial biogenesis. 
The Nrf2-ARE pathway is thus a signaling pathway responsible for controlling the expression of 
genes that are involved in eliminating oxidative products, such as NADPH quinone oxidoreductase-
1 (NQO-1) and electrophilic agents that increase the cell antioxidant capacity. In cases of PD and  
other  neurodegenerative  disorders,  the  activation  of  this  pathway  causes  a  potential 
neuroprotective response (Nguyen et al., 2009). 
The interaction of Nrf2 with the parkinsonian protein DJ-1 may provide another link between Nrf2 
function and PD. Upon oxidative stress, the transcriptional modulation activity of DJ-1 allows to 
stabilize Nrf2 by preventing its interaction with Keap1 and its consequently degradation leading to 
the translocation of Nrf2 into the nucleus (Clements et al., 2006). 
Figure 3 : Nrf2 activation by DJ-1 (Lee et al., 2009)
It was first believed that when Nrf2 was activated by cellular signals in times of stress, it would  
break  from  Keap1  and  translocate  from  the  cytosol  into  the  nucleus.  However,  it  has  been 
discovered that due to Nrf2’s unstable nature, it can also translocate into  the nucleus during times 
of non-stress within the cell in order to receive stability (Nguyen at al., 2009). 
Further understanding of the functions of the mentioned target mitochondrial proteins, DJ-1 in 
particular, has the potential to provide insight on the pathogenesis of PD. For this investigation, we 
set out to continue to investigate how DJ-1 is impaired in PD-related conditions by exposing the 
human neuroblastoma cell  line SH-SY5Y to a Rotenone-induced oxidative stress and measuring 
their  viability.  We  also  investigated  the  potential  link  between  DJ-1’s  protection  against 
neurotoxicity and the activation of the Nrf2-ARE pathway, ultimately leading to a neuroprotective 
response. 
1.9 Glia’s neuroprotective role in PD
The  last  purpose  of  our  study  was  to  investigate  how  glial  neurotrophic  products  promote 
proliferation and neuroprotection by exposing the cell line SH-SY5Y to rotenone and  to a medium 
from a culture of the human glioblastoma cell line U-87 MG.
Neuroglia  provides  support  and  protection  for  neurons  in  both  central  nervous  system  and 
peripheral nervous system. Glia’s main functions are to facilitate the development and plasticity of 
the  nervous  system,  to  regulate  the  fluid  surrounding  neurons  and  their  synapse,  to  supply 
nourishment and oxygen to neurons, to destroy pathogens and remove dead neurons. 
In particular astrocytes, the most abundant type of macroglial cells in central nervous system, have 
numerous  projections  that  link  neurons  to  their  blood  supply  while  forming  the  blood-brain 
barrier.  Furthermore,  they  regulate  the  external  neural  environment  by  removing  excess  of 
potassium  ions  and  recycling  the  neurotransmitters  during  synaptic  transmission.  Astrocytes 
produce various substances, primarily ATP which is used to communicate with each other by gap 
junctions (“Studying the Nervous Systems of Humans and Other Animals” Purves et al., 2004).
A study performed by Larsen et al. in 2011 demonstrated that knockdown and knockout of DJ-1 
expression  in  astrocytes  impairs  astrocyte-mediated  neuroprotection  against  oxidative  stress. 
Therefore a recent study of Dukhande et al. in 2013 demonstrated that a co-culture of a human 
glioblastoma U-87 cell line could protect a neuroblastoma SK-N-SH cell line against mitochondrial 
dysfunction  and  apoptotic  death  induced  by  depletion  of  mitochondrial  glutathione  (GSH). 
Consequently,  neuroprotective  factor  are  secreted  by  astrocytes  and  are  indeed  potential 
candidates  for  rescuing  neurons  under  oxidative  stress  and  degeneration  such  as  Parkinson’s 
disease. 
2.  MATERIALS AND METHODS
2.1 Cell Cultures 
Human  neuroblastoma  SH-SY5Y  cells  were  cultured  in  a  media  containing   90%  Dulbecco’s 
Modified  Eagle’s  Medium  Ham’s  F-12  (DMEM)  enriched  with  2mM  L-Glutamine,  10%  heat 
inactivated Fetal Bovine Serum, 1% penicillin/streptomycin and 1% non-essential amminoacids. 
Human  Glioblastoma Astrocytoma U-87  MG cells  were  cultured  in  Eagle's  Minimum Essential  
Medium (EMEM) supplemented with 2mM L-Glutamine, 10% heat inactivated Fetal Bovine Serum, 
1% penicillin/streptomycin and 1% non-essential amminoacids.
Cells  were  maintained as  monolayer  under  sterile  conditions  in  a  25  cm²  surface  area/10  ml 
volume  (T-25)  flask.  They  were  cultured  in  an  incubator  with  95%air  and  5%  CO2  humidified 
atmosphere at 37°C. The morphology of the cells was recorded using a camera (Primovert HDcam) 
attached to an inverted light microscope (Primovert, ZEISS).
2.2 Trypsinization and Cell Count
Medium was aspirated from T-25 flask and the attached monolayer of SH-SY5Y cells were gently  
washed twice in phosphate buffered saline (PBS). Then cells were exposed to 1X trypsin in an  
incubator at 37°C for 5 minutes. Detached cells were then suspended in fresh medium and placed 
in a centrifuge (MIRKO 200) for 5 minutes at 300rpm. Resulting cell pellet was re-suspended in a 
1:10 dilution of medium and counted using a haemocytometer under a microscope. 
2.3 Cell Treatments
Cell viability under oxidative stress conditions was determined by placing 5000 cells of SH-SY5Y in  
each well of the half of two 96-wells plates and were then allowed to grow for 48 hours. Half of the 
first plate was treated with rotenone at the concentrations of 0, 0.1, 0.5, 2.5 and 10 µM. Half of 
the second plate was treated with hydrogen peroxide (H2O2) at the concentration of 0, 100, 200, 
500, 1000 and 2000 µM. Both plates were then incubated at 37°C, the rotenone for 48 hours and  
the H2O2 for 24 hours. 
Cell viability in presence of potential neuroprotective factors and oxidative stress conditions, was 
determined by placing 2500 SH-SY5Y cells in each well of a 96-well microplate that were allowed to 
grow for  48-72 hours.  Then half  plate  medium was aspirated and replaced with a  mixture  of 
DMEM and EMEM media (1:1) and Rotenone at the concentrations of 0, 0.1, 0.5, 2.5 and 10 µM. 
The medium of the other half-side of the plate was aspirated and replaced with the previous 
rotenone concentrations and a mixture of DMEM and GLIOMA media (1:1). This glioma medium 
was formerly collected from a human glioblastoma astrocytoma U-87 MG culture, centrifuged and 
stored at 4°C.
Cell proliferation in presence of different media was measured in both 96-well plates and T-25 flask 
culture environments, by separately placing SH-SY5Y cells with DMEM medium as a control, with a 
mixture of DMEM-EMEM and a mixture of DMEM-Glioblastoma cultured medium. The cells were 
incubated in T-25 flask for 2 and 3 days, while 5000 cells were plated in each well of a 96-wells 
plate and incubated for 1, 2 and 3 days. 
2.4 Cell Viability: MTT Assay 
Cell viability was primarily monitored by measuring cellular mitochondrial activity. At the end of 
each treatment, 10ul of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoulium bromide) were 
added to each well and then incubated for 1 hour at 37°C. The culture medium was aspirated from 
each well and then the resulting product was solubilized in 100 µl dimethyl sulfoxide (DMSO). After 
agitating for 2 minutes on a plate shaker, the absorbance for each plate was taken at 570nm in a 
plate reader (UVM 340 plate reader and Harrier 15/80 Omega BMG Labtech microplate reader).  
Same methods but different solutions volumes,  were used to measure the viability of the cell  
suspension extracted from T-25 flask.
2.5 Cell Viability: Neutral red Assay 
Cell  viability  was determined also by measuring cellular  lysosomal  activity.   At  the end of  the 
treatment, the cultured medium was removed from each well, replaced with 100ul of Red Medium 
(1:10 dilution of Neutral Red solution 40mg/10ml in growth medium) and incubated for 2 hours at 
37°C. The Red medium was then carefully aspirated from each well and the resulting product was 
solubilized in 100 µl of Red Solution (made with 50% Ethanol, 49% deionised water and 1% glacial 
acetic acid). After agitating for 10 minutes on a plate shaker, the absorbance for each plate was 
read at  540 nm in  UVM 340 plate  reader  and Harrier  15/80 Omega BMG Labtech microplate  
reader.
2.6 Protein Estimation
The samples for protein estimation were performed by an incubation of four T-25 flasks containing 
SH-SY5Y  cells  for  72  hours  in  a  37°C  humidified  atmosphere,  followed  by  a  treatment  with 
Rotenone at 0, 0.1, 0.5, 2.5uM concentrations for 48 hours. Cells were then collected from each 
flask  by using a cell  scrapper  and spun down by a centrifuge at  300rpm for  5  minutes.  Once 
collected, the resulting cell pellets were washed twice with 1ml of PBS and spun a final time in a 
microfuge MIKRO 200 at 10,000rpm for 5 minutes. Triplicates of protein standards were prepared 
using bovine serum albumin (BSA), RIPA extraction buffer and distilled water. SH-SY5Y cell samples 
Rotenone treated were prepared by adding 250ul of RIPA buffer, containing phosphate inhibitor, to 
each sample and then mixed using a Whirlimixer for 1 minute. Samples were then spun in the 
microfuge at 14,000rpm for 10 minutes and 10ul of each sample resulting supernatant was added 
to 90ul of distilled water. 
According to the Lowry method, 1ml of Lowry reagent (96.3% sodium carbonate/sodium hydroxide 
solution, 1% (w/v) copper sulphate solution, and 2.7% (w/v) NaK-tartrate solution) was added to 
each sample and allowed to incubate at room temperature for 15 minutes. 100ul of diluted Folin-
Ciocalteau  (diluted  1:1  with  distilled  water)  was  added  to  each  tube,  vortexed  mixed,  and 
incubated for 30 minutes at room temperature. 
100ul of each sample (standards and cell samples) were plated out into a 96-well plate and the 
absorbance was read at 750nm using a POLAR star Omega plate reader. Calibration curve was then 
created using Microsoft Excel and estimated protein concentration of each unknown cell sample 
was measured using the curve as a standard. 
2.7 SDS-PAGE and semi-dry Western Blotting
Protein samples were prepared using calculated volumes from protein estimation (section 2.6) in  
order to contain 15ug of protein and equally matched in volume of 2x Laemmli running buffer.  
Samples were then heated in a Techne Hot Block at 100°C for 5 minutes. A protein standard was 
loaded into the stacking gel of a 12% polyacrylamide Mini-PROTEAN TGX Precast Gels (Bio-RAD) 
along with the heated protein samples, then the gel was ran at 150V for 1 hour. 
Proteins  separated  by  sodium dodecyl  sulphate  polyacrylamide  gel  electrophoresis  (SDS-PAGE) 
were transferred onto a nitrocellulose membrane by a Semi-Dry Western Blotting.  Using a transfer  
buffer (48mM Tris,  39mM glycine, 0.0375% SDS, and 20% methanol) to soak the transfer filter 
paper and the nitrocellulose, a filter paper sandwich formed of the gel and the membrane was 
created  on  a  Western  Blot  transferring  block  and  the  protein  gel  was  transferred  to  the 
nitrocellulose paper by allowing it to run in the block for 1 hour at 50mA. 
2.8 Copper Stain
Blotting efficiency was checked by staining with a reversible copper stain (copper phthalocyanine 
3,4’,4’,,4’’’ tetrasulphonic acid tetrasodium salt). Nitrocellulose membrane was immersed in copper 
stain for 2-3 minutes with agitation and then rinsed using distilled water. Once protein bands were  
visible, nitrocellulose was cut as needed based on the size of the appropriate targeted proteins.  
De-staining of the copper stain was then achieved by performing multiple washes with drops of  
4M NaOH in distilled water until the blue stain was completely removed. 
2.9 Immunoprobing 
The  immunoprobing  of  the  targeted  DJ-1  and  NRF-2  proteins  was  achieved  by  a  previous 
incubation of the nitrocellulose membranes in a blocking solution, made up of 3% (w/v) Marvel  
milk powder diluted in tris buffer saline (TBS) at pH 7.4 and 0.1% Tween20, at room temperature 
for one hour while using a plate shaker. Blocked membranes were then rinsed with distilled water  
and incubated with primary antibodies (anti-DJ-1 and anti-Nrf2 rabbit  antibodies)  in a 3% BSA 
solution overnight at 4°C. Unbound primary antibodies were removed by shaking in a TBS 1X-
Tween20 solution for 10 minutes and repeating the wash five times. Nitrocellulose membrane was 
then  incubated  with  an  alkaline  phosphate  conjugated-secondary  antibody  solution  (anti-IgG 
rabbit  antibodies  diluted  1:100  in  3%  Marvel  milk  and  TBS-Tween)  for  two  hours  at  room 
temperature  while  shaking.  Blots  were  finally  washed  five  times  in  TBS-Tween  and  rinsed  in 
distilled water for 2 minutes at room temperature. 
2.10 Alkaline Phosphate Detection 
The protein bands on the nitrocellulose paper were detected by using a substrate buffer of 0.75M 
Tris at pH 9.5 containing 0.13mM of Nitro Blue tetrazolim (NBT) and 0.29mM 5-bromo-4-chloro-3-
indolyl phosphate (BCIP). Substrate buffer solution was poured over nitrocellulose, covered and 
placed on a plate shaker. Formation of bands was checked at 5 minute intervals and the resulting  
bands were read in a Bio Rad ChemiDoc MP imaging system. 
2.11 Statistical Analysis 
All  data is  expressed as the means of each replicated or triplicated experiment.  The statistical  
significance of the data was tested by Student’s t-test for single comparisons. p value < 0.05 was 
considered statistically significant for each case. All statistical analyses tests were performed using 
Microsoft Excel 2010.
3.  RESULTS  
3.1 Effects of mitochondrial impairment and oxidative stress on SH-SY5Y cells. 
In order to reproduce a neural  cell  model of  PD, human neuroblastoma SH-SY5Y cell  line was 
treated with multiple concentrations  of  Rotenone,  a  known mitochondrial  Complex I  inhibitor. 
Alongside the Rotenone tests, treatments with H2O2, a common known oxidant, were performed 
in  order  to  compare  the  effects  on  cell  viability  between  the  two  compounds.  Rotenone 
concentrations  used  were  0.1uM,  0.5uM,  2.5uM,  10uM  and  0uM  as  the  control.  H2O2 
concentrations were 100uM, 200uM, 500uM, 1000uM, 2000uM and 0uM as the control. 
Both treatments onto the cells caused various responses including changes in the morphology of 
viable cells  and cell  shrinkage leading to possible apoptosis  (Figures 4 and 5).  As  exhibited in  
Figures  4-D  and  4-E,  cell  death  occurred  at  the  concentration  of  2.5uM and 10uM Rotenone 
represented by a reduction in cell  volume and a loss of the spherical  cell  shape. A similar cell  
morphology resulted at the concentration of 500uM and 1000uM H2O2 (Figures 5-D and 5- E),  
whereas 2000uM H2O2 (Figure 5-F) resulted only in a few rounded dead cells. 
Suddenly the cell viability was detected by MTT and Neutral Red assays. 
The  MTT  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide)  tetrazolium  reduction 
assay is based on the characteristic of viable cell with active metabolism to convert MTT into a 
purple coloured formazan product with an absorbance near 570nm. When cells die, they lose the  
ability to convert MTT into formazan, thus colour formation serves as a marker of only the viable 
cells.  The  formazan product  accumulates  as  an  insoluble  precipitate  inside cells  that  must  be 
solubilized in DMSO prior to recording absorbance readings.  The amount of signal generated is 
dependent  on  several  parameters  including:  the  concentration  of  MTT,  the  length  of  the 
incubation  period,  the  number  of  viable  cells  and  their  and  metabolic  activity.  All  of  these 
parameters should be considered when optimizing the assay conditions to generate a sufficient 
amount  of  product  that  can  be  detected  above  background. Thus  the  quantity  of  formazan, 
presumably  proportional  to  the  number  of  viable  cells,  is  measured  by  recording  changes  in 
absorbance at 570nm using a plate reading spectrophotometer. The exact cellular mechanism of 
MTT reduction into formazan is not well understood, but likely involves reaction with NAD(P)H or  
similar  reducing  molecules  that  transfer  electrons  to  MTT.  However,  speculation  in  the  early 
literature involving specific mitochondrial NAD(P)H-dependent enzymes has led to the assumption 
that MTT measures mitochondrial activity (Riss et al., 2004-2013). 
The Neutral Ned uptake assay is based on the ability of viable cells to incorporate and bind the 
neutral red dye in the lysosomes. This cationic dye penetrates cell membranes by passive diffusion 
and  concentrates  in  the  lysosomes,  where  it  binds  to  anionic  and  phosphate  groups  of  the 
lysosomal matrix by electrostatic hydrophobic bonds. At physiological pH the dye presents a net 
charge  close  to  zero  enabling  it  to  penetrate  the  membranes  of  the  cell,  whereas  inside  the 
lysosomes,  where  a  proton  gradient  maintains  a  low  pH,  the  dye  becomes  charged  and  it  is 
retained. When the cell dies or the pH gradient is reduced, the dye is not retained. Consequently, 
the amount of retained dye is proportional to the number of viable cells. In addition, the uptake of 
neutral red by viable cells can be modified by alterations in cell surface or lysosomal membranes 
thus it is possible to distinguish between viable, damaged or dead cells. The neutral red dye is then 
extracted from the viable cells using an Ethanol solution and the absorbance of the solubilized dye 
is quantified using a spectrophotometer (Repetto et al., 2008). In conclusion intrinsic differences 
between the two assays allowed to measure cell viability comparing mitochondrial and lysosomal 
activity. 
As shown in Figures 6 and 7, the percentage of cell viability of neuroblastoma cells by MTT assay  
decreased in each case, from 100% at the control to 10% at 2.5uM of Rotenone and to 6% at  
1000uM of H2O2. 
In Figures 8 and 9 is shown that the percent cell viability decreased also in each case obtained by 
the Neutral Red assay, from the 100% at the control to 57% at 2.5uM of Rotenone and to 21% at  
1000uM of H2O2. Possible outliers are present between 2.5uM and 10uM of Rotenone, with a rise  
of 9%, and between 1000uM and 2000uM, with a rise of 10%. 
Data collected were considered statistically significant by the use of a Student T-test, containing a 
p-value < 0.05. In MTT assay, 0.1uM of Rotenone and 100uM of H2O2 were determined to do not 
have a statistically significant drop in percent cell viability compared to the control, whereas 10uM 
of Rotenone and 2000uM of H2O2 did not have statistical importance compared to the previous 
respective treatment concentration. In Neutral Red assay, 100uM and 200uM H2O2, 0,1um and 
0,5uM of rotenone were determined to do not have a statistically significant drop in percent cell 
viability compared to the control; whereas 10uM of Rotenone and 2000uM of H2O2 did not have  
statistical importance compared to the previous respective treatment concentration.
Figure 4 : Pictures of human neuroblastoma SH-SY5Y cells after 48 hours Rotenone treatment. 
A) Un-treated neuronal cells used as the control; B) cells treated with 0.1uM of Rotenone showed a slight 
shrink on dendrites; C) cells treated with 0.5uM of Rotenone showed a decrease in cell size and some dead  
cells can be observed; D) cells treated with 2.5uM of Rotenone displayed a vast change in morphology  
alongside apoptosis; E) cells treated with 10uM of Rotenone displayed large apoptosis, most of the cells 
were dead. Images taken with a Zeiss model microscope using  ZEN imaging software. 
Figure 5 : Pictures of human neuroblastoma SH-SY5Y cells after 24 hours H2O2 treatment. 
A) Un-treated neuronal cells used as the control; B) cells treated with 100uM of H2O2 showed a strong 
shrink in morphology and minimal cell death; C) cells treated with 200uM of H2O2 showed a vast drop in 
cell size and some dead cells can be observed; D) cells treated with 500uM of H2O2 displayed apoptosis; E)  
cells treated with 1000uM of H2O2 displayed apoptosis; F) cells treated with 2000uM of H2O2 showed large  
apoptosis, most of the cells were dead. Images taken with a Zeiss model microscope using  ZEN imaging  
software. 
Figure 6 : Graphical representation of MTT viability assay performed on human neuroblastoma SH-SY5Y cell 
line after 48 hours treatment with multiple concentrations of rotenone. Data collected were considered  
statistically significant by the use of a Student T-test, containing a  p-value < 0.05. 0.1uM was determined to  
do not have a statistically significant drop in percent cell viability compared to the control, whereas 10uM 
did not have statistical importance compared to the previous treatment. 
Figure 7 : Graphical representation of MTT viability assay performed on human neuroblastoma SH-SY5Y cell 
line  after  24 hours  treatment  with  multiple  concentrations  of  Hydrogen peroxide.  Data  collected were 
considered statistically significant by the use of a Student T-test, containing a p-value < 0.05. 100uM was  
determined to do not have a statistically significant drop in percent cell viability compared to the control,  
whereas 2000uM did not have statistical importance compared to the previous treatment. 
Figure 8 : Graphical representation of Neutral Red viability assay performed on human neuroblastoma SH-
SY5Y cell  line after 48 hours treatment with multiple concentrations of  Rotenone.  Data collected were 
considered statistically significant by the use of a Student T-test, containing a p-value < 0.05. 0,1 uM and 
0,5uM were determined to do not have a statistically significant drop in percent cell viability compared to  
the control, whereas 10uM did not have statistical importance compared to the previous  treatment. 
Figure 9 : Graphical representation of Neutral Red viability assay performed on human neuroblastoma SH-
SY5Y cell line after 24 hours treatment with multiple concentrations of Hydrogen peroxide. Data collected  
were considered statistically significant by the use of a Student T-test, containing a p-value < 0.05. 100uM 
and 200uM were determined to do not have a statistically significant drop in percent cell viability compared  
to the control, whereas 2000uM did not have statistical importance compared to the previous  treatment.
3.2. Possible Rotenone-induced modulation of  DJ1 and Nrf2 proteins on SH-SY5Y.
In order to estimate the protein amount within Rotenone-treated SH-SY5Y cells pellet samples,  
protein estimation by Lowry Method was used as a precursor technique for SDS-PAGE gel and 
Western  Blotting  analyses.  Thirteen  known  protein-containing  solutions  of  BSA  were  used  to 
construct  a  standard  curve  based  on  the  absorbance  of  each  solution.  Then  the  average 
absorbance of each Rotenone concentration was substituted in the calculated trend line equation 
of the known BSA standard curve in order to estimate the protein concentration within each cell  
sample and to calculate the volumes of each sample needed to provide an estimated 15ug/ul of 
protein.  Table  1  and  2,  with  their  respective  graphs,  showed  the  linear  equation  used  to 
determinate estimated protein concentration and the data calculated for each sample chosen to 
test for SDS-PAGE and Western Blot analysis.
SH-SY5Y sample 1
Rotenone Concentration Average Abs at 750 nm Protein (ug/ul) Volume (15ug protein)
0 uM 0,1090 1,103 14
0,1  uM 0,1190 1,448 10
0,5  uM 0,0913 0,494 30
2,5  uM 0,1090 1,103 14
Table 1 : BSA standard curve and table of values as a result of the protein estimation from the first sample  
of Rotenone-treated SH-SY5Y cells. The last column represent the calculated volumes needed to provide an 
estimated 15ug/ul of protein.
SH-SY5Y sample 2
Rotenone Concentration Average Abs at 750 nm Protein (ug/ul) Volume ul (15ug protein)
0 uM 0,10200 0,956 16
0,1  uM 0,10200 0,956 16
0,5  uM 0,09533 0,733 20
2,5  uM 0,08933 0,533 28
Table 2 :  BSA standard curve and table of values as a result of the protein estimation from the second 
sample of Rotenone-treated SH-SY5Y cells. The last column represent the calculated volumes needed to 
provide an estimated 15ug/ul of protein.
Estimated proteins were then ran by SDS-PAGE in order to separate all the proteins within the cell  
samples  by  size.  A  protein  standard  ladder  was  loaded  alongside  our  samples  allowing  to 
determinate which band represented the size of the target proteins.
Once the proteins run was finished, the gel was transferred onto a nitrocellulose membrane by a 
Semi-Dry Western Blotting,  ideal for detecting proteins with a lower molecular weight that bound 
to the membrane by hydrophobic interactions. The protein bands of each lane on the membrane 
were initially visualized by a reversible Copper Stain (Figure 10). In order to cut the nitrocellulose in 
two sections for the Western Blot analysis, the standard ladder was used to determinate which 
was the appropriated band, visible by Copper Stain, of each target protein: based on the published 
literature, DJ-1 has been found to be around 20kDa and Nrf2 to be around 68kDa. Both sections of  
the  membrane  were  first  incubated with  their  respective  primary  antibodies  that  would  bind 
specifically to DJ-1 and Nrf2, then with a secondary Blocking solution containing  anti-IgG rabbit  
antibodies  that  allowed to  visualize  the target  protein  bands  on  the nitrocellulose  by alkaline 
phosphate detection (Figure 11 and Figure 12). 
Figure 10 : Image of reversible Copper Stain performed after nitrocellulose membrane transfer in order to 
check if transfer was successful and to appropriately cut the membrane for the following Western Blotting.
Lines 1-4 consist of the first SH-SY5Y cells sample, lines 5-8 consist of the second sample. The start  
of  each line  is  the control  (lanes  1  and 5)  then it  works  up  to 0.1uM, 0.5uM, and 2.5uM of  
Rotenone. 
Figure 11 : Blot of mitochondrial protein DJ-1 (20kDa) in Rotenone treated SH-SY5Y cell samples. Lines 1-4 
consist of the first SH-SY5Y cells sample, lines 5-8 consist of the second sample. The start of each line is the  
control  (lanes  1  and  5)  then  it  works  up  to  0.1uM,  0.5uM,  and  2.5uM  of  Rotenone.  Lines  1  and  5  
representing the control have very intense bands.
Figure 12 : Blot of mitochondrial protein Nrf2 (68kDa) in Rotenone treated SH-SY5Y cell samples. Lines 1-4 
consist of the first SH-SY5Y cells sample, lines 5-8 consist of the second sample. The start of each line is the  
control (lanes 1 and 5) then it work up to 0.1uM, 0.5uM, and 2.5uM of Rotenone.
Visually, the membrane showing DJ-1 has very intense bands at Rotenone 0uM concentration (lane 
1 and lane 5) but only in the second sample (lanes 5-8) a decrease of the boldness of the bands  
can be seen as a rise of the Rotenone concentration. The membrane exhibiting Nrf2 did not show 
much variability between bands, probably because of the low intensity of the dye, except for the 
Rotenone 0uM samples (lane 1 and lane 5) where bands are slightly more intense. Therefore lane 
3 (Rotenone 0.5uM sample) and lane 6 (Rotenone 0.1uM sample) showed tiny bands that were 
almost invisible. 
Suddenly, volumes of each protein were measured in an imaging system based on the band size  
and band colour intensity (BioRad ChemiDOC).  DJ-1 volumes did not show variability between 
treatments,  except  for  2.5uM that  in  both  samples  were higher  than the  control  (Figure  13). 
Therefore neither Nrf2 volumes showed a particular variability linked to Rotenone concentrations: 
in  both  samples  they  dropped  at  0.1uM  and  0.5uM  Rotenone,  then  they  increase  at  2.5uM 
Rotenone but with two different patterns (Figure 14). 
In order to determine a possible link between the two target proteins, a ratio of DJ-1 to Nrf2 was 
calculated using each measured integrated volume and summarised in Table 3. We expected to 
found a proportional correspondence between proteins volumes, as DJ-1 is a watch of Rotenone-
induced oxidative stress that activates Nrf2 letting its translocation in the nucleus, but actually our  
results were not linked.
Unfortunately this experiment was not successful, thus any conclusions could not be supported by 
unclear results. Probably the lack of a Loading Control did not allow us to check that the lanes have  
been evenly  loaded with sample  or  to quantify the protein  amounts  in  each lane if  even the 
transfer have not occurred.
 
Figure 13 : Graphical representation of DJ-1 integrated volumes measured from blots by imaging system. 
Figure 14 : Graphical representation of Nrf2 integrated volumes measured from blots by imaging system. 
Sample I
Rotenone Treatment DJ-1 Volume Integr. Nrf2 Volume Integr. Ratio Normalised
0 uM 47670980 10016805 4,7591003 1
0,1 uM 27101736 3334449 8,1278004 1,70784389
0,5 uM 44835703 892600 50,230454 10,5546112
2,5 uM 55160469 3472800 15,883572 3,33751569
Sample II
Rotenone  Treatment DJ-1 Volume Integr. Nrf2 Volume Integr. Ratio Normalised
0 uM 77302043 6299200 12,271724 1
0,1 uM 76649628 1210900 63,299718 5,15817649
0,5 uM 59974848 4731951 12,674444 1,03281692
2,5 uM 81266172 6926640 11,732409 0,95605221
Table 3: Summary of measured integrated volumes and ratio of DJ-1 and Nrf2 present in SH-SY5Y  Western 
blot analysis. 
3.3 U-87 MG cultured medium protection of SH-SY5Y cells against Rotenone-induced cell death.
In order to investigate how Glial cells attend particular neuronal dysfunctions like mitochondrial 
damage, the human glioblastoma astrocytoma U-87 MG cell line was incubated in EMEM medium 
for 72 hours and the produced medium was collected, centrifuged and stored at 4°C before being 
used to treat SH-SY5Y cells. Neuroblastoma cells were first placed on a 96-wells plate and allowed 
to grow for 3 days with single DMEM medium. Then half plate medium was aspirated and replaced 
with a mixture of  DMEM and EMEM medium (1:1) treated with 0,  0.1,  0.5,  2.5 and 10uM of 
rotenone. The medium of the other half-side of the plate was aspirated and replace a mixture of  
DMEM and GLIOMA cultured medium (1:1) treated with the same five rotenone concentrations. 
After 48 hours the cell viability was measured by the MTT reduction. 
As shown in Figure 16, with EMEM medium the percent cell viability of SH-SY5Y cells decreased 
from  100%  at  the  control  to  7%  at  10uM  rotenone  concentration,  conversely  with  GLIOMA 
cultured medium the cell viability decreased from 100% to 22%. Therefore both 2.5uM and 10uM 
treatments exhibited higher cell survival with GLIOMA cultured medium (23 and 22%) comparing 
with EMEM medium (15 and 7%). These percentages were confirmed by the images in Figure 15, 
where it was possible to see a few healthy cells at the higher concentrations of rotenone (Figures  
15-H and 15-L).
Data  collected  were  considered  statistically  significant  by  the  use  of  a  Student  T-test.  All 
concentrations  of  rotenone of  both media treatments  contained a p-value < 0.05,   except  for 
0.1uM rotenone which did not have a statistically significant drop in percent cell viability compared 
to the control. 

Figure 15 : Pictures of human neuroblastoma SH-SY5Y cells after co-treatment with Rotenone and cultured 
medium from human glioma U-87 MG cell line.
A) cells co-treated with Emem medium and 0uM of Rotenone, used as a first control; B) cells co-treated 
with  Glioma medium and  0uM of  Rotenone,  used  as  a  second control  C)  cells  co-treated with  Emem  
medium and 0.1uM of Rotenone; D) cells co-treated with Glioma medium and 0.1uM of Rotenone; E) cells 
co-treated with Emem medium and 0.5uM of Rotenone; F) cells co-treated with Glioma medium and 0.5uM  
of Rotenone; G) cells  co-treated with Emem medium and 2.5uM of  Rotenone; H) cells  co-treated with  
Glioma medium and 2.5uM of Rotenone; I) cells co-treated with Emem medium and 10uM of Rotenone;    L) 
cells co-treated with Glioma medium and 10uM of Rotenone.
Figure 16 : Graphical representation of MTT assay performed on human neuroblastoma SH-SY5Y cells after 
48 hours co-treatment  with Rotenone and cultured medium from human glioma U-87 MG cell line. 
3.4 U-87 MG cultured medium modulation of SH-SY5Y cells proliferation.
Since  the  significant  results  obtained  with  the  Rotenone  treatment,  the  last  purpose  was  to 
investigate if SHSY5Y cells modified their proliferation pattern in presence of Glioma media. 
The first approach was to plate Neuroblastoma cells in a 96-well plate with three different kinds of  
medium: DMEM medium as a control, a mixture of DMEM and EMEM medium (1:1), a mixture of 
DMEM and Glioblastoma cultured medium (1:1). MTT viability assay was performed after 1 day, 2  
days and 3 days of growth. 
Looking  at  the  pictures  (Figures  17,  18  and  19)  it  has  been  possible  to  find  a  visual  higher 
concentration  of  cells  with  DMEM-EMEM  medium  treatment  and  DMEM-Glioma  medium 
treatment compared to the control of each day of the experiment.  
As shown in the graphical representation in Figure 20, the percent cell viability of SHSY5Y cells 
increased from the control in both DMEM-EMEM medium and DMEM-Glioma medium treatments 
and mostly after 1 day: the 100% cell viability of the control rose to 331% with EMEM medium and 
to 240% with Glioma medium. After 2 and 3 days, the cell viability of the cells in EMEM and Glioma 
was decreased from the first treatment but still higher than the control. Therefore in each case the 
percent viability of the cells grown with Glioma medium was lower than the percent viability of the 
ones grown with EMEM medium, with a drop of 91% after 1 day, 89% after 2 days and 78% after 3  
days. 
Figure 17 :  Pictures of human neuroblastoma SH-SY5Y cells after 1 day of growth in plates with different 
kinds of media: A) only DMEM medium as the control, B) DMEM medium and EMEM medium, C) DMEM  
medium and cultured medium from Human Glioma U-87 MG cell line.
Figure 18 :  Pictures of human neuroblastoma SH-SY5Y cells after 2 days of growth in plates with different 
kinds of media: A) only DMEM medium as the control, B) DMEM medium and EMEM medium, C) DMEM  
medium and cultured medium from Human Glioma U-87 MG cell line.
Figure 19 :  Pictures of human neuroblastoma SH-SY5Y cells after 3 days of growth in plates with different 
kinds of media: A) only DMEM medium as the control, B) DMEM medium and EMEM medium, C) DMEM  
medium and cultured medium from Human Glioma U-87 MG cell line.
Figure 20 :  Graphical representation of MTT assay performed on human neuroblastoma SH-SY5Y cell line 
grown for 1-2-3 days in plates with different types of medium: DMEM medium as a control, DMEM medium 
mixed with EMEM medium and DMEM medium mixed with cultured medium from human glioma U-87 MG 
cell line.
The second approach pertained the incubation of SH-SY5Y cells in T-25 flasks with the three types 
of  medium  of  the  previous  experiment:  DMEM  as  a  control,  DMEM  and  EMEM,  DMEM  and 
glioblastoma cultured medium. MTT viability assay was performed after 2 and 3 days of growth as 
a parameter of mitochondrial metabolic activity, while a cell count was previously performed to 
estimate the cell number of each flask. Cells were detached from the flask by a cell scraper, a few  
microliters of the resulting suspension were diluted and used for the cell count then the rest of the  
suspension was incubated with MTT. 
As exhibited in Figures 21 and 22, there was not a relevant difference in the cell density between 
the treatment after two days as after three. However, cells grown for three days with the GLIOMA 
medium (Figures 21-C) presented more death cells and more signs of apoptosis compared to the 
cells of the control and the cells within EMEM. This would be explained by the lack of nourishment 
that characterized the medium already cultured over three days within glioblastoma cells. 
The visual cell density was then compared with a cell count. As shown in Figure 23, after two days 
of  treatment the cells  grown with  GLIOMA medium were 2250/ul  whereas  control  cells  were 
2130/ul and cells grown with EMEM medium were 1780/ul. As expected from the visual analysis,  
after  three  days  the  concentration  of  the  cells  grown  with  GLIOMA medium  was  found  very 
reduced (1490/ul) and also control cells were less than the day before (1630/ul). Interestingly cells 
grown with EMEM medium were found to be slightly increased from 1780/ul to 1940/ul.
Figure 24 is a graphical representation of the percent cell viability obtained by MTT assay in order 
to  compare  cell  concentration  with  cell  metabolic  activity.  It  did  not  show  much  variability 
between treatments except for the GLIOMA medium, where the cell viability after two days was 
11% lower than the control and 15% than EMEM medium. 
Figure 21 :  Pictures of human neuroblastoma SH-SY5Y cells after 2 days of growth in  different kind of 
media: A) only DMEM medium, B) DMEM medium and EMEM medium, C) DMEM medium and cultured 
medium from human glioma U-87 MG cell line.
Figure 22 :  Pictures of human neuroblastoma SH-SY5Y cells after 3 days of growth in  different kind of 
media: A) only DMEM medium, B) DMEM medium and EMEM medium, C) DMEM medium and cultured 
medium from human glioma U-87 MG cell line.
Figure 23 : Graphical representation of the cell count performed on human neuroblastoma SH-SY5Y cell line  
grown in three different kind of flasks: with DMEM medium as a control, with EMEM medium and with 
cultured medium from human glioma U-87 MG cell line.
Figure 24 :  Graphical representation of MTT viability assay performed on human neuroblastoma SH-SY5Y 
cell line grown in three different kind of flasks: with DMEM medium as a control, with EMEM medium and 
with cultured medium from human glioblastoma U-87 MG cell line.
4.  CONCLUSIONS
The mitochondrial protein DJ-1, the transcription factor protein Nrf2 and the neural support glial  
cells are particularly popular in recent studies involving the possibility that they could potentially 
play a role in altering the neurodegenerative effects of PD. 
In this project, we set out to investigate how DJ-1 and Nrf2 are affected by the known parkinsonian 
reagent  rotenone  in  a  neuronal  cell  model  of  human  neuroblastoma  SH-SY5Y  cells.  We  also 
evaluated  whether  or  not  the  presence  of  a  medium  collected  from  a  Human  glioblastoma 
astrocytoma U-87 MG culture could spur proliferation or  provide protection against  rotenone-
induced apoptosis in SH-SY5Y cells.
Primarily, we tested how exactly the SH-SY5Y cells were affected by rotenone. We then compared 
the rotenone effects against the effects of the known oxidant H2O2 using MTT and Neutral Red 
viability assays. Previous studies (Cassarino et al., 1997. Betarbeth et al., 2000. Kurshnareva et al., 
2002) determined that rotenone toxicity in Neuroblastoma cells depends on a direct interaction 
with Complex I, which partially inhibits the enzyme and leaks electrons enhancing ROS production. 
Therefore cells expressing the rotenone-insensitive single-subunit NADH dehydrogenase of yeast 
(NDI1), that acts as a copy for the entire mammalian Complex I, were resistant to rotenone toxicity 
(Sherer  at  al.  2003).  Thus  rotenone  toxicity  indeed appears  to result  primarily  from oxidative  
damage.
In both cases the cell viability decreased as expected as the concentrations of rotenone and H2O2 
became higher. The two higher concentrations of rotenone (2.5uM and 10uM) and three higher 
concentration of H2O2 (500uM, 1000uM and 2000uM) were also immediately affected physically.  
Looking at the images they were able to induce cellular apoptosis, with a considerable change in 
overall cellular morphology and with little remaining viable cells. So we were able to conclude that  
the higher rotenone and H2O2 concentrations which were found to not be statistically significant, 
were simply due to the fact that overall cell death had occurred in those case and both viability  
assays were unable to correctly distinguish cell death levels.
It is important to note that there was an observed colour change in the media of the cells in the 
96-well plate. As opposed to the normal orange coloration of the media due to the presence of  
phenol red, the media in the 0.1uM and 0.5uM rotenone-treated cells had turned yellow. It is  
possible that due to the mitochondrial complex 1 inhibition from the rotenone thus the cells were 
using  the  glucose  and other  nutrients  present  in  the media  to undergo glycolysis  in  order  to 
maintain energy production within the cells.   
We next investigated if the presence of Rotenone on SH-SY5Y cells had an effect on DJ-1 and Nrf2,  
and if there was a link between DJ-1 and the activation of Nrf2 for the Nrf2-ARE pathway. In a 
study performed by Clements et al. in 2006, they demonstrated that DJ-1 helps to stabilize Nrf2 
and triggers the activation of the Nrf2-ARE pathway: in fact DJ-1 prevents Keap1 from binding to 
Nrf2  and  allows  its  translocation  into  the  nucleus  from the  cytoplasm.  Likewise,  an  observed 
decrease in DJ-1 also exhibited a decrease in other anti-oxidative proteins regulated by the Nrf2-
ARE pathway, which led the researchers to believe that DJ-1 played a role in the overall activation 
of this combative response. 
We expected to find a correspondence between DJ-1 and Nrf2 band intensities, calculated from 
the Western Blot, activated by the rotenone-induced oxidative stress. Unfortunately our results did 
not show a proper pattern that could confirm the rise of the measured band intensities as the 
Rotenone  concentration  became  higher,  thus  we  could  not  demonstrate  experimentally  our 
assumptions.
Assuming that Glial cells support synaptic contacts and maintain the signaling abilities of neurons, 
previous studies have analysed how these cells are activated as a result of neuronal conditions of 
stress: modulating synaptic action by controlling the uptake of neurotransmitters, modulating the 
rate of nerve signal propagation, providing a scaffold for some aspects of neural development, and 
maintain, in a variety of ways, an appropriate chemical environment for neuronal signaling 
(“Studying the Nervous Systems of Humans and Other Animals” Purves et al., 2004). In order to 
investigate how Glial cells attend particular neuronal dysfunctions like mitochondrial damage, a 
human glioblastoma U-87 MG cell line was cultivated in order to produce a medium rich of growth 
factors and signal molecules thought to be useful for neural survival. MTT viability assays were 
performed again with the presence of Glioma cultured medium compared to the un-cultured 
EMEM medium and they appeared to play a role in combating cellular apoptosis. In fact, at the 
highest concentrations of Rotenone used, 2.5uM and 100uM respectively, Glioma medium had the 
most success in fighting off apoptosis, whereas at the middle concentration was not as successful 
as the EMEM control medium. This leads us to believe that the cells treated with those two 
concentrations of Rotenone (0.1uM and 0.5uM) were effectively not enough injured to trigger an 
intensive defensive response. 
Our  results  are  consistent  to  a  study  performed  by  Duckhande  et  al.  in  2013,  where  they  
demonstrated  the  neuroprotective  role  of  glioblastoma  U-87  secreted  factor  against 
neuroblastoma  SK-N-SH  glutathione  depletion-induced  apoptosis.  They  indeed  considered 
astrocytes factors as potential candidates for rescuing neurons undergoing oxidative stress.
Finally, for our last set of experiments we set out to investigate if glial cells attended also in neural 
proliferation. Consequently we incubated neuroblastoma cells with DMEM medium as a control, a 
mixture of DMEM and EMEM, a mixture of DMEM and glioblastoma cultured medium in 96-well  
plates for 1,2,3 days and in T-25 flasks for 2 and 3 days. 
Observing our results, it would seem that the Glioma medium used did not appear to provide 
much  difference  in  spurring  the  cell  growth.  In  fact  both  MTT  viability  assay  and  cell  count 
performed on the cells grown in the flasks showed an increased viability in both EMEM and Glioma 
treatments compared to the control. Moreover MTT assay performed on the plates did not show 
variability or particular differences between the cells grown in the three mixture medium during all  
the three treatment periods.
We could  then confirm the results  of  the  previous  experiment:  glioblastoma medium did not 
containe molecules that promote proliferation but that support and defend neural cells against 
oxidative injuries indeed.
It is interesting to notice that SH-SY5Y cells viability, most of the times, was higher when they were  
cultured with EMEM medium than with either the control or the Glioma medium. This can be 
explained by the fact that neuroblastoma cells found in EMEM a better culture medium and that 
the cultured Glioma medium was less rich of nourishments, as it was already cultured for 3 days  
within U-87 MG cells, so the cells had to grow in extreme conditions.
Given the chance to continue with this experiment, it would be interesting to see if the results for  
our MTT viability assays would change with the introduction of U-87 MG cultured-medium pre-
treatment in the cultures. Therefore it would be beneficial to repeat the analysis of DJ-1 and Nrf2 
levels  within  SH-SY5Y  cells  and  to  test  if  they  would  change  with  samples  co-treated  with 
glioblastoma cultured-medium  and  Rotenone.  Finally,  in  order  to  see  which  results  would  be 
obtained after rotenone treatments, it would be of interest to set similar experiments on U-87 MG 
cells and subsequently to analyse which neuroprotective molecules would be found within the 
glioblastoma cultured-medium.
Further studies that investigate glial cells factors as well other avenues that work toward activating 
the  Nrf2-ARE  pathway,  could  further  provide  promising  strategies  against  oxidative  stress  and 
neurodegeneration in Parkinson’s disease. 
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